These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 30061030)

  • 1. Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy.
    Yang S; Lu D; Ouyang P
    Bioorg Med Chem Lett; 2018 Sep; 28(17):3004-3008. PubMed ID: 30061030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents.
    Yang S; Lu D; Ouyang P
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1731-1735. PubMed ID: 29706422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.
    Osuma AT; Xu X; Wang Z; Van Camp JA; Freiberg GM
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126603. PubMed ID: 31416667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of neuronal KCNQ channel modulators.
    Gribkoff VK
    Expert Opin Ther Targets; 2003 Dec; 7(6):737-48. PubMed ID: 14640909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.
    Qi J; Zhang F; Mi Y; Fu Y; Xu W; Zhang D; Wu Y; Du X; Jia Q; Wang K; Zhang H
    Eur J Med Chem; 2011 Mar; 46(3):934-43. PubMed ID: 21296466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel K
    Seefeld MA; Lin H; Holenz J; Downie D; Donovan B; Fu T; Pasikanti K; Zhen W; Cato M; Chaudhary KW; Brady P; Bakshi T; Morrow D; Rajagopal S; Samanta SK; Madhyastha N; Kuppusamy BM; Dougherty RW; Bhamidipati R; Mohd Z; Higgins GA; Chapman M; Rouget C; Lluel P; Matsuoka Y
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3793-3797. PubMed ID: 30327146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The specific slow afterhyperpolarization inhibitor UCL2077 is a subtype-selective blocker of the epilepsy associated KCNQ channels.
    Soh H; Tzingounis AV
    Mol Pharmacol; 2010 Dec; 78(6):1088-95. PubMed ID: 20843955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction.
    Zavaritskaya O; Zhuravleva N; Schleifenbaum J; Gloe T; Devermann L; Kluge R; Mladenov M; Frey M; Gagov H; Fésüs G; Gollasch M; Schubert R
    Hypertension; 2013 Jan; 61(1):151-9. PubMed ID: 23184384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KCNQ2/3 openers show differential selectivity and site of action across multiple KCNQ channels.
    Zhang D; Thimmapaya R; Zhang XF; Anderson DJ; Baranowski JL; Scanio M; Perez-Medrano A; Peddi S; Wang Z; Patel JR; DeGoey DA; Gopalakrishnan M; Honore P; Yao BB; Surowy CS
    J Neurosci Methods; 2011 Aug; 200(1):54-62. PubMed ID: 21723881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand modulation of KCNQ-encoded (K
    Naffaa MM; Al-Ewaidat OA
    Eur J Pharmacol; 2021 Sep; 906():174278. PubMed ID: 34174270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological modulation of the voltage-gated neuronal Kv7/KCNQ/M-channel alters the intrinsic excitability and synaptic responses of pyramidal neurons in rat prefrontal cortex slices.
    Peng H; Bian XL; Ma FC; Wang KW
    Acta Pharmacol Sin; 2017 Sep; 38(9):1248-1256. PubMed ID: 28603289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers.
    Lloyd J; Schmidt JB; Rovnyak G; Ahmad S; Atwal KS; Bisaha SN; Doweyko LM; Stein PD; Traeger SC; Mathur A; Conder ML; DiMarco J; Harper TW; Jenkins-West T; Levesque PC; Normandin DE; Russell AD; Serafino RP; Smith MA; Lodge NJ
    J Med Chem; 2001 Nov; 44(23):3764-7. PubMed ID: 11689063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased susceptibility to acetylcholine in the entorhinal cortex of pilocarpine-treated rats involves alterations in KCNQ channels.
    Maslarova A; Salar S; Lapilover E; Friedman A; Veh RW; Heinemann U
    Neurobiol Dis; 2013 Aug; 56():14-24. PubMed ID: 23583611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
    Zagorchev P; Apostolova E; Kokova V; Peychev L
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of M-type (KCNQ) potassium channels as a novel strategy to reduce stroke-induced brain injury.
    Bierbower SM; Choveau FS; Lechleiter JD; Shapiro MS
    J Neurosci; 2015 Feb; 35(5):2101-11. PubMed ID: 25653366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel Kv7 channel opener as a treatment for epilepsy.
    Davoren JE; Claffey MM; Snow SL; Reese MR; Arora G; Butler CR; Boscoe BP; Chenard L; DeNinno SL; Drozda SE; Duplantier AJ; Moine L; Rogers BN; Rong S; Schuyten K; Wright AS; Zhang L; Serpa KA; Weber ML; Stolyar P; Whisman TL; Baker K; Tse K; Clark AJ; Rong H; Mather RJ; Lowe JA
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4941-4944. PubMed ID: 25987375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels.
    Haick JM; Byron KL
    Pharmacol Ther; 2016 Sep; 165():14-25. PubMed ID: 27179745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide.
    Schleifenbaum J; Köhn C; Voblova N; Dubrovska G; Zavarirskaya O; Gloe T; Crean CS; Luft FC; Huang Y; Schubert R; Gollasch M
    J Hypertens; 2010 Sep; 28(9):1875-82. PubMed ID: 20577128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.